PCSK9 inhibitors for treating hypercholesterolemia

References

• Global Burden of Disease 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1084–1150.
   PubMed Web of Science ®Google Scholar
• Gorenek B, Blomstrom Lundqvist C, AL ET. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014;16(11): 1655–1673.
   PubMed Web of Science ®Google Scholar
• Witt BJ, Brown RD Jr, Jacobsen SJ, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143:785–792.
   PubMed Web of Science ®Google Scholar
• Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease. early assessment and treatment. J Am Coll Cardiol. 2009 Feb;53(3):254–263.
   PubMed Web of Science ®Google Scholar
• Valbusa A, Ingrassia S, Rosa GM et al. Takotsubo cardiomyopathy and torsade de pointes in myasthenic crisis: be aware of QT prolongation. Am J Emerg Med. 2013 Dec;31(12):1717–1718.
   PubMed Web of Science ®Google Scholar
• Valbusa A, Paganini M, Secchi G, et al. What happened to a thrombus during apical ballooning syndrome: a case report. Swiss Med Wkly. 2013 May17;143:w13797.
   PubMed Web of Science ®Google Scholar
• Núñez-Gil IJ, Molina M, Bernardo E, et al. Tako-tsubo syndrome and heart failure: long-term follow-up. Rev Esp Cardiol (Engl Ed). 2012 Nov;65(11):996–1002.
   PubMed Web of Science ®Google Scholar
• kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. Ann Intern Med. 1979;90:85–91.
   PubMed Web of Science ®Google Scholar
• Miller M Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM. 2009 Sept;102(9):657–667.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease, 1: evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Reiner Ž Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Reiner Ž Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol. 2015;12(10):565–575.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Rosa GM, Carbone F, Parodi A et al. Update on the efficacy of statin treatment in acute coronary syndromes. Eur J Clin Invest. 2014 May;44(5):501–515.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(SupplC):C2–C12.
   PubMedGoogle Scholar
• Giugliano RP, Sabatine MS Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015 June 23;65(24):2638–2651.
   PubMed Web of Science ®Google Scholar
• Reiner Ž PCSK9 inhibitors in clinical practice: expectations and reality. Atherosclerosis. 2018 Mar;270:187–188
   PubMed Web of Science ®Google Scholar
• Zang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. Published online 2015 Jun 23, BMC Medicine2011;3:123.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Parhofer KG, Babirak SP, et al.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J, 2016:37:3588–3595.
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document. Evolocumab (REPATHA®, AMG 145). 2015 June 10 [cited 2017 Mar 2]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf
   Google Scholar
• Praluent (alirocumab) injection. FDA document – BLA 125559. FDA center for drug evaluation and research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2015 June 9.
   Google Scholar
• Repatha (evolocumab) injection prescribing information. Amgen; 2015 Aug 27. [cited 2016 Aug 3]. Available from: http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf
   Google Scholar
• Stein EA, Wasserman SM, Dias C, et al. AMG-145. Drugs Future. 2013;38:451–459.
   Web of Science ®Google Scholar
• Sanofi Aventis and Regeneron Pharmaceuticals Inc. Praluent (alirocumab injection) manufacturer’s prescribing information. 2015 July [cited 2015 Aug 3; Accessed 2016 Aug 3]. Available from: http://products.sanofi.us/praluent/praluent.pdf
   Google Scholar
• Roth EM, Diller P Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol. 2014;10:183–199
   PubMedGoogle Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of pcsk9 inhibitors from molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20(4):20.
   PubMed Web of Science ®Google Scholar
• Bittner V. Pleiotropic effects of pcsk9 (proprotein convertase subtilisin/kexin type 9) inhibitors? Circulation. 2016;134(22):1695–1696.
   PubMed Web of Science ®Google Scholar
• Tavori H, Giunzioni I, Fazio S. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):126–132.
   PubMed Web of Science ®Google Scholar
• Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016;253:214–224.
   PubMed Web of Science ®Google Scholar
• Wu CY, Tang ZH, Jiang L, et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem. 2012; 359 (1–2): 347–358
   PubMed Web of Science ®Google Scholar
• Li J, Liang X, Wang Y, et al. Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis. Mol Med Rep. 2017;16(2):1817–1825.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02729025 ( ANITSCHKOW trial).
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02941016 (Vascular Inflammation and Cholesterol Lowering Therapy).
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03258281 ( Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention).
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02984982 ( ODYSSEY JIVUS trial).
   Google Scholar
• National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02992301 ( Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab).
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02959047 ( A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease).
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03067844 ( PACMANAMItrial).
   Google Scholar
• Kühnast S, Van der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103–2112.
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Windecker S, Buhayer A, et al. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin Cardiol. 2018;41(12):1513–1520.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Watts GF, Robinson JG, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program). Am J Cardiol. 2017;119(1):40–46.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016;57(6):1086–1096.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. PCSK9 inhibitors–past, present and future. Expert Opin Drug Metab Toxicol. 2015;11(10):1517–1521.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc Drugs Ther. 2016;30(5):473–483.
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 2015;169(6):906–915.e13.
   PubMed Web of Science ®Google Scholar
• El Shahawy M, CP C, DJ B, et al. Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). Am J Cardiol. 2017;120(6):931–939.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–769
   PubMed Web of Science ®Google Scholar
• Roth EM, Mckenney JM ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27–37.
   PubMed Web of Science ®Google Scholar
• Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS i randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140–3148.
   PubMed Web of Science ®Google Scholar
• Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–146.
   PubMed Web of Science ®Google Scholar
• Roth EM, Moriarty PM, Bergeron J, et al. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:254–262.
   PubMed Web of Science ®Google Scholar
• Stroes E, Guyton JR, Lepor N, et al. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016 Sept 13;5(9).pii: e003421.
   Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–2540.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341–350.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–2548.
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117(1):40–47.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–1590.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509.
   PubMed Web of Science ®Google Scholar
• Santos R, Hovingh GK, Blom D et al. Long-term Evolocumab use in subjects with homozygous and severe heterozygous familial hypercholesterolemia: primary results of the Taussig trial. J Am Coll Cardiol. Mar 2019;73(9 Supplement 1):1715.
   Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123
   PubMed Web of Science ®Google Scholar
• Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017 Dec 9;6(12) pii: e006910.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Farnier M, Robinson JG, et al. Efficacy and safety of alirocumab in individuals with diabetes mellitus: pooled analyses from five placebo-controlled phase 3 studies. Diabetes Ther. 2018;9(3):1317–1334.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4(5):403–410.
   PubMed Web of Science ®Google Scholar
• Stroes E, Robinson JG, Raal FJ, et al. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018;41(10):1328–1335
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Can Lp(a) Lowering against background statin therapy really reduce cardiovascular risk? Curr Atheroscler Rep. 2019 Mar 7;21(4):14.
   PubMed Web of Science ®Google Scholar
• Steg PG, Szarek M, Bhatt DL, et al. Effect of alirocumab on mortality after acute coronary syndromes [ published correction appears in circulation. 2019 jul 23;140(4):e171].Circulation. 2019;140(2):103–112.
   PubMed Web of Science ®Google Scholar
• Jukema JW, Zijlstra LE, Bhatt DL, et al. Effect of alirocumab on stroke in ODYSSEY OUTCOMES [ published online ahead of print, 2019 nov 11]. Circulation. 2019. DOI:10.1161/CIRCULATIONAHA.119.043826
   Web of Science ®Google Scholar
• Gouni-Berthold I The efficacy of anti-PCSK9 antibodies: results from recent trials. Atherosclerosis. Supplements 2017;30:9–18.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Descamps OS, Fraass U et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 2016;82:1412–1443.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Schulze V et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40–51.
   PubMed Web of Science ®Google Scholar
• Cheng C, Sun S, Zhou Y, et al. Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: a meta-analysis. Biomed Rep 2016;5:541–547.
   PubMed Web of Science ®Google Scholar
• Toth PP, Descamps O, Genest J et al. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation 2017;135:1819–1831.
   PubMed Web of Science ®Google Scholar
• Sattar N, Toth PP, Blom DJ et al. Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus. Am J Cardiol. 2017;120:1521–1527.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–950.
   PubMed Web of Science ®Google Scholar
• Ray KK, Colhoun HM, Szarek M et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 7 Aug;8:618–625.
   Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al.Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390:1962–1971.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J. 2018;39:374–381.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al.Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–643.
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J Immunogenicity of engineered antibodies. Methods. 2005;36:3–10
   PubMed Web of Science ®Google Scholar
• Ridker PM, Tardif JC, Amarenco P, et al.Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376:1517–1526.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al.Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539.
   PubMed Web of Science ®Google Scholar
• Zhao HP, Xiang BR Discontinued cardiovascular drugs in 2013 and 2014. Expert Opin Investig Drugs. 2015;24:1083–1092.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al.Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017; 2:598–607.
   PubMed Web of Science ®Google Scholar
• Farnier M, Hovingh GK, Langslet G, et al.Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018;278:307–314.
   PubMed Web of Science ®Google Scholar
• Roth EM, Goldberg AC, Catapano AL, et al.Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017;376:1589–1590.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin e and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117:731–741.
   PubMed Web of Science ®Google Scholar